Physician profile
Scot Mckay
NPI 1588710198
$827.70
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $135 · 2022: $24.55 · 2023: $70.93 · 2024: $76.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $188.24 | 2019-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $113.22 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $85.03 | 2019 | |
| Allergan, INC. | $80.92 | 2019-2020 | |
| Lundbeck LLC | $76.51 | 2019-2020 | |
| Abbvie INC. | $51.62 | 2023-2024 | |
| Bausch Health US, LLC | $46.25 | 2019 | |
| Shire North American Group INC | $39.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.87 | 2019 | |
| Vanda Pharmaceuticals INC. | $35.72 | 2019 | |
| Axsome Therapeutics, INC. | $29.80 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $24.55 | 2022 | |
| Alkermes, INC. | $18.59 | 2023 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scot Mckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.